Agios Pharmaceuticals Inc AGIO

US Biotechnology

$30.02 ▼ -8.34% ($-2.73)

Open $33.34

Prev Close $32.75

Day Range $29.94 – $33.34

52W Range $22.24 – $46.00

Market Cap $1.79B

Beta 0.59

EPS (TTM) $-7.25

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2013-07-24
Shares Out.	59,470,000
Website	agios.com/ ↗
Phone	13026587581
Employees	540
Revenue	$20.7M
Gross Profit	$19.4M
Net Income	-$99.1M
Free Cash Flow	-$384.7M
Total Assets	$1.18B
Total Liabilities	$75.9M
Equity	$1.11B

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Agios Pharmaceuticals Inc is a publicly traded company under the ticker symbol AGIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.